288 related articles for article (PubMed ID: 35409080)
21. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
22. Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.
Ouédraogo ZG; Biau J; Kemeny JL; Morel L; Verrelle P; Chautard E
Mol Neurobiol; 2017 Oct; 54(8):5780-5797. PubMed ID: 27660268
[TBL] [Abstract][Full Text] [Related]
23. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
24. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas.
Zou H; Wen C; Peng Z; Shao YΥ; Hu L; Li S; Li C; Zhou HH
Oncol Rep; 2018 Feb; 39(2):501-510. PubMed ID: 29207176
[TBL] [Abstract][Full Text] [Related]
25. PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
Rasheed BK; Stenzel TT; McLendon RE; Parsons R; Friedman AH; Friedman HS; Bigner DD; Bigner SH
Cancer Res; 1997 Oct; 57(19):4187-90. PubMed ID: 9331072
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
27. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
28. [Malignant glioma].
Okamura K
Nihon Rinsho; 1995 Nov; 53(11):2678-83. PubMed ID: 8538025
[TBL] [Abstract][Full Text] [Related]
29. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
30. Molecular Characteristics of Thalamic Gliomas in Adults.
Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
[TBL] [Abstract][Full Text] [Related]
31. Hypermethylation of the RASSF1A gene in gliomas.
Gao Y; Guan M; Su B; Liu W; Xu M; Lu Y
Clin Chim Acta; 2004 Nov; 349(1-2):173-9. PubMed ID: 15469871
[TBL] [Abstract][Full Text] [Related]
32. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas.
Kazarian E; Marks A; Cui J; Darbinyan A; Tong E; Mueller S; Cha S; Aboian MS
Sci Rep; 2021 Jul; 11(1):14377. PubMed ID: 34257334
[TBL] [Abstract][Full Text] [Related]
33. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
34. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
[TBL] [Abstract][Full Text] [Related]
35. Molecular biology of pediatric gliomas.
Raffel C
J Neurooncol; 1996; 28(2-3):121-8. PubMed ID: 8832457
[TBL] [Abstract][Full Text] [Related]
36. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.
Lo HW; Cao X; Zhu H; Ali-Osman F
Clin Cancer Res; 2008 Oct; 14(19):6042-54. PubMed ID: 18829483
[TBL] [Abstract][Full Text] [Related]
37. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
38. Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts.
Broniscer A; Hwang SN; Chamdine O; Lin T; Pounds S; Onar-Thomas A; Chi L; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
Brain Pathol; 2018 Jan; 28(1):112-120. PubMed ID: 28032389
[TBL] [Abstract][Full Text] [Related]
39. Targeting of endoplasmic reticulum (ER) stress in gliomas.
Markouli M; Strepkos D; Papavassiliou AG; Piperi C
Pharmacol Res; 2020 Jul; 157():104823. PubMed ID: 32305494
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic and Tumor-Suppressive Functions of NOTCH Signaling in Glioma.
Parmigiani E; Taylor V; Giachino C
Cells; 2020 Oct; 9(10):. PubMed ID: 33076453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
